Business Wire

AM-PHARMA-B.V.

Share
AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology . The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI. The publication is available now online at https://www.frontiersin.org/articles/10.3389/fmed.2022.931293/abstract .

This study provides further insight into the mechanism of action of ilofotase alfa, showing that adenosine receptor signaling plays a role in the activity of the drug by restoring homeostasis through conversion of extracellular ATP into adenosine activating anti-inflammatory adenosine receptor signaling in common AKI animal models. The 1000 U/Kg dose tested in this study is, comparable to the dose currently being tested in the global phase III pivotal study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury (SA-AKI).

“We are very encouraged by the findings of this study, as these data further validate the role of ilofotase alfa in protecting the kidney during episodes of acute kidney injury,” said Maarten Kraan, MD, PhD, Chief Medical Officer of AM-Pharma. “The results reported by the esteemed authors of this publication show that augmentation of adenosine signaling is a key component of the mechanism of action of ilofotase alfa in rodent ischemia-reperfusion induced AKI and provide additional evidence of the potential of ilofotase alfa as a treatment option for AKI.”

About Ilofotase Alfa

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active. The recombinant enzyme displays exquisite activity towards dephosphorylating and detoxifying damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), ATP, ADP and other extracellular substrates that drive acute inflammation, coagulation and microvascular ischemia found in kidney following sepsis or ischemia-induced damage. Research has shown that ATP dephosphorylation has a double effect in protecting against kidney injury. When the pro-inflammatory ATP is dephosphorylated, the resulting adenosine further reduces inflammation through the activation of the immunosuppressive adenosine A2a receptor pathway.

About AM-Pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for sepsis-associated acute kidney injury and is now in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals. Find out more about us online at: www.am-pharma.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bitfury Launches $1 Billion Initiative to Advance Ethical Emerging Technologies18.11.2025 16:11:00 CET | Press release

The company will begin deploying funds as early as Q4 2025 Today, Bitcoin miner turned technology incubator Bitfury announced its pivot to an investment firm with the launch of its $1 billion funding initiative, which seeks to back a new generation of ethical innovators. The firm’s new mission is to close the gap between the accelerating pace of technological progress and the slower evolution of ethical development — a disconnect it sees as a root cause of many global challenges. By supporting mission-driven founders, the company seeks to accelerate ventures that embed ethics, transparency, and human values at the core of emerging technologies. Bitfury’s new chapter as an investment firm builds on its pioneering legacy while expanding its role from technology provider to global catalyst for responsible innovation — ensuring the digital economy develops with integrity and long-term sustainability. Bitfury was originally founded in 2011 as a bitcoin miner, but over the past 15 years has

Interactive Brokers Expands Global Market Access with the Taipei Exchange18.11.2025 16:00:00 CET | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced access to the Taipei Exchange (TPEx), further expanding its global reach. Eligible clients of Interactive Brokers can now trade equities, ETFs, and Taiwan Depositary Receipts (TDRs) listed on TPEx, alongside products from over 160 global exchanges from a single platform. This extends the opportunity set available to global investors seeking Asian exposure, including the growth potential afforded by emerging small and medium-sized companies listed on the TPEx. Interactive Brokers is one of the few global trading platforms connected to TPEx, a leading Asian exchange for shares of small and medium-sized enterprises (SMEs). Through TPEx, clients can diversify their portfolios to include emerging, high-tech, and creative industries, as well as SMEs and micro-enterprises across Taiwan’s developing economy. To simplify trading, Interactive Brokers will facilitate TPEx trades with an automatic FX conversion be

Aspect Expands Cloud Workforce Experience and Developer Tools to New Regions and Introduces AI-Powered Forecasting18.11.2025 15:00:00 CET | Press release

New release brings predictive intelligence, regional expansion, and enhanced employee performance tools to contact center operations. Aspect, a leading provider of cloud-based workforce management solutions, today announced its Q4 2025 product release, delivering AI-powered predictive forecasting for call volume, regional expansion into Canada, UK, and Europe, and new employee performance capabilities. The release represents a significant step forward in Aspect's mission to empower workforces with intelligent, modern tools that drive operational efficiency and employee engagement. AI-Driven Forecasting Brings New Precision and Agility to Workforce Planning The enhanced Forecast Dashboard introduces Predictive Forecasting with built-in AI intelligence. This new feature automatically generates four-week call volume forecasts that refresh daily, eliminating manual setup and enabling planners to make faster, more confident scheduling decisions. By analyzing historical data with advanced al

FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler18.11.2025 15:00:00 CET | Press release

Deep Illumio integration and continued VMware NSX and Zscaler support, security teams can now operationalize Zero Trust at enterprise scale. FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler. By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale. “The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.” Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and

Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy18.11.2025 15:00:00 CET | Press release

Multi-year strategic partnership empowers Silicon Labs to maximize SAP ECC 6.0 value, accelerate transformation and avoid costly upgrades and disruption Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Silicon Labs has selected Rimini Street as its strategic partner to maximize the value of its SAP ECC 6.0 investment. This collaboration provides the U.S.-based semiconductor manufacturer with long-term SAP maintenance and professional services to accelerate modernization without costly upgrades or business disruption. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118277544/en/ Silicon Labs Partners with Rimini Street to Build a Future-Ready SAP Strategy Partnership Reduces Technical Debt and Accelerates Modernization Sili

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye